Skip to content
Neurizon Therapeutics LTD. episode artwork

Feb 9, 2026 10 min

Neurizon Therapeutics LTD.

from OTCQB Podcast Hosted by OTC Markets Group

Neurizon Therapeutics LTD. (OTCQB: NUZTF) is an Australian clinical-stage biotech company focused on developing treatments for neurodegenerative diseases, with their lead program aimed at ALS. Michael Thurn, CEO and Managing Director of Neurizon, joins us to discuss their mission to address neurodegenerative diseases through its lead ALS therapy View Podcast Transcript

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Neurizon Therapeutics LTD.

0:00 10:12

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OTCQB Podcast?

This episode is 10 minutes long.

When was this OTCQB Podcast episode published?

This episode was published on February 9, 2026.

Can I download this OTCQB Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.